var title_f10_53_11088="Supracondylar fracture line";
var content_f10_53_11088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Supracondylar fracture line",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Orientation of fracture lines. A) The typical transverse fracture line originates just above the epicondyles and courses through the supracondylar area (arrows). B) In the lateral projection, the fracture line is usually also transverse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11088=[""].join("\n");
var outline_f10_53_11088=null;
var title_f10_53_11089="Normal impulse conduction";
var content_f10_53_11089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Schema of normal impulse conduction in the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sinoatrial node (SAN) generates an action potential that is conducted through the right and left atria, resulting in atrial contraction. The impulse is then conducted through the atrioventricular node (AVN), activating the ventricular myocardium, resulting in contraction of the right and left ventricle.",
"    <div class=\"footnotes\">",
"     SVC: superior vena cava; IVC: inferior vena cava; PV: pulmonary veins; LAA: left atrial appendage; RAA: right atrial appendage.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11089=[""].join("\n");
var outline_f10_53_11089=null;
var title_f10_53_11090="Endoscopy showing ulcers";
var content_f10_53_11090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Upper endoscopy showing shallow ulcers in the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing multiple discrete shallow ulcers in the distal third of the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Canalejo E, Duran FG, Cabello N, Martinez JG. Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature. Medicine 2010; 89:204. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11090=[""].join("\n");
var outline_f10_53_11090=null;
var title_f10_53_11091="Mebendazole: Pediatric drug information";
var content_f10_53_11091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mebendazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"    see \"Mebendazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/29/1492?source=see_link\">",
"    see \"Mebendazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vermox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anthelmintic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"      see \"Mebendazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pinworms: Single chewable tablet (100 mg); may need to repeat after 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Whipworms, roundworms, hookworms: 100 mg twice daily, morning and evening on 3 consecutive days; if patient is not cured within 3-4 weeks, a second course of treatment may be administered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capillariasis: 200 mg twice daily for 20 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 100 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food; tablet can be crushed and mixed with food, swallowed whole, or chewed",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of enterobiasis (pinworm infection), trichuriasis (whipworm infection), ascariasis (roundworm infection), and hookworm infections caused by",
"     <i>",
"      Necator americanus",
"     </i>",
"     or",
"     <i>",
"      Ancylostoma duodenale",
"     </i>",
"     ; drug of choice in the treatment of capillariasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9500697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mebendazole may be confused with metroNIDAZOLE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, exanthema, itching, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, hemoglobin decreased, leukopenia, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, GGT increased, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, cylindruria, glomerulonephritis, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions (anaphylactic, anaphylactoid)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mebendazole or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy and children &lt;2 years of age are relative contraindications since safety has not been established",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): Mebendazole may enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): Mebendazole may enhance the adverse/toxic effect of MetroNIDAZOLE (Topical). Particularly the risk for Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases mebendazole absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; adverse pregnancy outcomes have not been observed following use in pregnancy (Diav-Citrin, 2003; Gyorkos, 2006).  Treatment of pinworm in pregnancy may be considered; however, the CDC suggests postponing therapy until the third trimester when possible (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For treatment of trichuriasis, ascariasis, hookworm, or mixed infections, check for helminth ova in the feces within 3-4 weeks following the initial therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively and irreversibly blocks uptake of glucose and other nutrients in susceptible intestine-dwelling helminths",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 2% to 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To liver, fat, muscle, plasma, and hepatic cysts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.8-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Variable (0.5-7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in feces as inactive metabolites with 5% to 10% eliminated in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hotez PJ, &ldquo;Hookworm Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(8):516-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11091/abstract-text/2671907 /pubmed\" id=\"2671907 \" target=\"_blank\">",
"        2671907",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12571 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11091=[""].join("\n");
var outline_f10_53_11091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191554\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048400\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048395\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191533\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048403\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048402\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500697\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191603\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048406\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048394\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299650\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191528\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048408\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191529\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386518\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048399\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048393\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048405\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=related_link\">",
"      Mebendazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/29/1492?source=related_link\">",
"      Mebendazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_53_11092="Sleep physiology in children";
var content_f10_53_11092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleep physiology in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Merrill S Wise, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Daniel G Glaze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Ronald D Chervin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11092/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/53/11092/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep is an active, dynamic physiologic process that has a critical impact on many aspects of health, daytime function, and development. During the first few years of life, a number of important developmental changes occur, leading to the expected adult",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will describe normal",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    patterns in infancy and childhood. This will provide background for an evaluative approach to sleep problems in children, which is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=see_link\">",
"     \"Assessment of sleep disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sleep stages and architecture in adults are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link\">",
"     \"Stages and architecture of normal sleep\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SLEEP STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two distinct sleep states have been identified based on specific physiological variables: rapid eye movement (REM) sleep and nonrapid eye movement (NREM) sleep. Standardized methods have been developed with regard to scoring sleep states in adults and infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      REM sleep is a physiologically distinct state, characterized by an activated EEG pattern (similar in some respects to wakefulness) associated with marked decrease in muscle tone and episodic bursts of rapid eye movements. Most dreaming occurs during REM sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NREM sleep is subdivided into three discrete stages based primarily on the EEG. The stages range from N1 (the lightest and often initial stage of sleep) to N3 (deep NREM sleep with a high arousal threshold); N3 corresponds to what was previously scored as stages 3 and 4.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    REM sleep was first characterized in 1953 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/8\">",
"     8",
"    </a>",
"    ]. In 1966, Roffwarg and colleagues sparked interest in the developmental aspects of sleep when they reported that newborns spend significantly more time in REM sleep as compared with older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/1\">",
"     1",
"    </a>",
"    ]. These investigators postulated that activation of key portions of the central and autonomic nervous system during REM sleep contributed to functional maturation. This hypothesis helped explain a number of differences in the sleep of infants compared with adults, as described below. Availability of all-night polysomnography in children has allowed more precise characterization of sleep architecture and has improved our understanding of the pathophysiology of many sleep disorders in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MATURATION OF SLEEP ARCHITECTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep-wake patterns become more diurnal, and sleep times gradually decrease from infancy through adolescence, as shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef82604 \" href=\"UTD.htm?14/0/14351\">",
"     figure 1",
"    </a>",
"    ). Sleep time of children in a given age group varies by as much as two hours. In addition, sleep patterns and behaviors have changed over time, such that sleep duration in equivalent age groups has declined, presumably reflecting socio-cultural changes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/9\">",
"     9",
"    </a>",
"    ]. Sleep times for children in the United States tend to be shorter than those in Europe and Australian series, especially on weekdays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In a survey of adolescents in the United States, more than 60 percent reported sleeping less than seven hours on weekday nights, substantially less than the 8.5 to 9.5 hours recommended by the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep in the healthy full-term newborn is distinguished from that of older individuals by [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Longer sleep duration (16 to 18 hours per 24 hours)",
"     </li>",
"     <li>",
"      REM sleep occurring at sleep onset",
"     </li>",
"     <li>",
"      Increased proportion of REM sleep",
"     </li>",
"     <li>",
"      REM-NREM cycle much shorter in duration as compared with older individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With maturation of the child's central nervous system, predictable changes occur, including gradual decrease in total sleep time and the proportion of REM sleep, progressive lengthening of the REM-NREM cycle, and shift to the adult pattern of sleep onset via NREM sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal older children and adolescents, sleep is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset via NREM sleep",
"     </li>",
"     <li>",
"      NREM sleep occupying approximately 75 percent of total sleep time",
"     </li>",
"     <li>",
"      REM and NREM sleep alternating throughout the night with a period of 90 to 100 minutes, and a progressive lengthening of the duration of REM sleep periods in the final one-third of the night.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sleep in adolescents is further characterized by [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decrease in slow wave sleep beginning in puberty and continuing into adulthood",
"     </li>",
"     <li>",
"      Physiological shift in sleep onset to a later time",
"     </li>",
"     <li>",
"      Increasing irregularity of sleep-wake patterns (primarily discrepancy between weeknights and weekend sleep patterns). &nbsp;",
"     </li>",
"     <li>",
"      Decrease in average sleep",
"      <strong>",
"       duration",
"      </strong>",
"      despite relatively stable sleep",
"      <strong>",
"       requirement",
"      </strong>",
"      of about nine hours",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion of sleep stages and sleep architecture in adults is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link\">",
"     \"Stages and architecture of normal sleep\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ASSOCIATION OF SLEEP DISORDERS WITH SLEEP STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinctive physiology of NREM sleep, REM sleep, or transitions between sleep and wakefulness can influence the timing and nature of specific sleep disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NREM sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;NREM parasomnias are characterized by impaired arousal from deep NREM sleep. Certain features of wakefulness and sleep occur simultaneously. These parasomnias tend to arise during the first one-third of the night when deep NREM sleep is common [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Disorders of arousal from NREM sleep include sleep walking, sleep terrors, and confusional arousals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H27172788#H27172788\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Disorders of arousal from non-rapid eye movement (NREM) sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     REM sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;REM sleep phenomena tend to occur in the latter portion of the sleep period when REM sleep predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These include nightmares, REM sleep behavior disorder, and sleep paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link&amp;anchor=H27172877#H27172877\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Parasomnias usually associated with rapid eye movement (REM) sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other respiratory problems (eg, obstructive sleep apnea) also tend to be more severe during REM sleep, although they may occur at any time during the night. This is because upper airway obstruction is often more severe during REM (when muscle tone is markedly reduced compared with wakefulness) and light NREM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=see_link&amp;anchor=H3#H3\">",
"     \"Mechanisms and predisposing factors for sleep related breathing disorders in children\", section on 'Changes in respiratory physiology during sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sleep-wake transition disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep-wake transition disorders occur during the transition from wakefulness to sleep, from sleep to wakefulness, or less commonly, during sleep stage transitions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/18\">",
"     18",
"    </a>",
"    ]. These disorders include rhythmic movement disorder, sleep starts, sleep talking, and nocturnal seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=see_link\">",
"     \"Sleepwalking and other parasomnias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     No association",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other parasomnias (eg, sleep bruxism and nocturnal enuresis) may occur during any sleep stage and at any time of the night [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11092/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      REM sleep is associated with marked decrease in muscle tone and episodic bursts of rapid eye movements. Most dreaming occurs during REM sleep. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sleep states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NREM sleep is subdivided into three discrete stages based primarily on the EEG. The stages range from N1 (lightest sleep) to N3 (deepest NREM sleep with a high arousal threshold). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sleep states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As compared with older children and adults, newborn infants have longer sleep duration and an increased proportion of REM sleep, and shorter REM-NREM cycles. Sleep-wake patterns become more diurnal, and sleep times gradually decrease from infancy through adolescence (",
"      <a class=\"graphic graphic_figure graphicRef82604 \" href=\"UTD.htm?14/0/14351\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Maturation of sleep architecture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NREM parasomnias are characterized by impaired arousal from deep NREM sleep, and tend to occur in the first one-third of the night. They include sleep walking, sleep terrors, and confusional arousals. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'NREM sleep'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      REM sleep phenomena tend to occur in the latter portion of the night, including nightmares, REM sleep behavior disorder, and sleep paralysis. Sleep apnea also tends to be more severe during REM sleep. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'REM sleep'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep-wake transition disorders include rhythmic movement disorder, sleep starts, sleep talking, and nocturnal seizures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sleep-wake transition disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/1\">",
"      Roffwarg HP, Muzio JN, Dement WC. Ontogenetic development of the human sleep-dream cycle. Science 1966; 152:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/2\">",
"      ASERINSKY E, KLEITMAN N. A motility cycle in sleeping infants as manifested by ocular and gross bodily activity. J Appl Physiol 1955; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     Anders TF, Sadeh A, Appareddy V. Normal sleep in neonates and children. In: Principles and Practice of Sleep Medicine in the Child, Ferber R, Kryger M (Eds), W.B. Saunders, Philadelphia 1995. p.7.",
"    </li>",
"    <li>",
"     Iber C, Ancoli-Israel S, Chesson AL, et al. The AASM Manual for the Scoring of Sleep and Associated Events, American Academy of Sleep Medicine, West Chester, IL 2007.",
"    </li>",
"    <li>",
"     A manual of standardized terminology, techniques and criteria for scoring of states of sleep and wakefulness in newborn infants, Anders T, Emde R, Parmelee AH (Eds), UCLA Brain Information Service, NINDS Neurological Information Network, Los Angeles 1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/6\">",
"      DEMENT W, KLEITMAN N. Cyclic variations in EEG during sleep and their relation to eye movements, body motility, and dreaming. Electroencephalogr Clin Neurophysiol 1957; 9:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/7\">",
"      DEMENT W, KLEITMAN N. The relation of eye movements during sleep to dream activity: an objective method for the study of dreaming. J Exp Psychol 1957; 53:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/8\">",
"      ASERINSKY E, KLEITMAN N. Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science 1953; 118:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/9\">",
"      Iglowstein I, Jenni OG, Molinari L, Largo RH. Sleep duration from infancy to adolescence: reference values and generational trends. Pediatrics 2003; 111:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/10\">",
"      Olds T, Maher C, Blunden S, Matricciani L. Normative data on the sleep habits of Australian children and adolescents. Sleep 2010; 33:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/11\">",
"      Blair PS, Humphreys JS, Gringras P, et al. Childhood sleep duration and associated demographic characteristics in an English cohort. Sleep 2012; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/12\">",
"      Eaton DK, McKnight-Eily LR, Lowry R, et al. Prevalence of insufficient, borderline, and optimal hours of sleep among high school students - United States, 2007. J Adolesc Health 2010; 46:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/13\">",
"      Sadeh A, Dahl RE, Shahar G, Rosenblat-Stein S. Sleep and the transition to adolescence: a longitudinal study. Sleep 2009; 32:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/14\">",
"      Gastaut H, Broughton RJ. A clinical and polygraphic study of episodic phenomena during sleep. Biol Psychiatry 1965; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     Keefauver SP, Guilleminault C. Sleep terrors and sleep walking. In: Principles and Practice of Sleep Medicine, 2nd ed, Kryger MH, Roth T, Dement WC (Eds), WB Saunders, Philadelphia 1994. p.567.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/16\">",
"      Fisher C, Byrne J, Edwards A, Kahn E. A psychophysiological study of nightmares. J Am Psychoanal Assoc 1970; 18:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/17\">",
"      Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986; 9:293.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11092/abstract/19\">",
"      Huang J, Karamessinis LR, Pepe ME, et al. Upper airway collapsibility during REM sleep in children with the obstructive sleep apnea syndrome. Sleep 2009; 32:1173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6354 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11092=[""].join("\n");
var outline_f10_53_11092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SLEEP STATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MATURATION OF SLEEP ARCHITECTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ASSOCIATION OF SLEEP DISORDERS WITH SLEEP STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NREM sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REM sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sleep-wake transition disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      No association",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6354\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6354|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/0/14351\" title=\"figure 1\">",
"      Typical sleep time in children by age group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=related_link\">",
"      Mechanisms and predisposing factors for sleep related breathing disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28473?source=related_link\">",
"      Sleepwalking and other parasomnias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=related_link\">",
"      Stages and architecture of normal sleep",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_53_11093="Oral lichen planus - tongue";
var content_f10_53_11093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Oral lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticular white plaques are present on the tongue. A small ulcer is visible in the upper left corner of this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Carl Allen, DDS, MSD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11093=[""].join("\n");
var outline_f10_53_11093=null;
var title_f10_53_11094="Cefoxitin: Drug information";
var content_f10_53_11094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefoxitin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/35/564?source=see_link\">",
"    see \"Cefoxitin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"    see \"Cefoxitin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10327785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mefoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14965749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cefoxitin For Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Second Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     I.M., I.V.: 1-2 g every 6-8 hours (I.M. injection is painful); up to 12 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Amnionitis and endomyometritis:",
"     </b>",
"     I.M., I.V.: 2 g every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Aspiration pneumonia, empyema, orbital cellulitis, parapharyngeal space, and human bites:",
"     </b>",
"     I.M., I.V.: 2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intra-abdominal infection, complicated, community acquired, mild-to-moderate:",
"     </b>",
"     I.V.: 2 g every 6 hours for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Liver abscess:",
"     </b>",
"     I.V.: 1 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mycobacterium species, not MTB or MAI:",
"     </b>",
"     I.V.: 12 g/day with amikacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Inpatients:",
"     </i>",
"     I.V.: 2 g every 6 hours",
"     <b>",
"      plus",
"     </b>",
"     doxycycline 100 mg I.V. or 100 mg orally every 12 hours until improved, followed by doxycycline 100 mg orally twice daily to complete 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Outpatients:",
"     </i>",
"     I.M.: 2 g",
"     <b>",
"      plus",
"     </b>",
"     probenecid 1 g orally as a single dose, followed by doxycycline 100 mg orally twice daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Perioperative prophylaxis:",
"     </b>",
"     I.M., I.V.: 1-2 g 30-60 minutes prior to surgery (may repeat in 2-5 hours intraoperatively) followed by 1-2 g every 6-8 hours for no more than 24 hours after surgery depending on the procedure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"      see \"Cefoxitin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Perioperative prophylaxis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &gt;3 months and Children: 30-40 mg/kg 30-60 minutes prior to surgery followed by 30-40 mg/kg/dose every 6 hours for no more than 24 hours after surgery depending on the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate infection:",
"     </b>",
"     I.M., I.V.: Infants &gt;3 months and Children: 80-100 mg/kg/day in divided doses every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe infection:",
"     </b>",
"     I.M., I.V.: Infants &gt;3 months and Children: 100-160 mg/kg/day in divided doses every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maximum dose:",
"     </i>",
"     12 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Administer 1-2 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Administer 1-2 g every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-9 mL/minute: Administer 0.5-1 g every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;5 mL/minute: Administer 0.5-1 g every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Moderately dialyzable (20% to 50%); administer a loading dose of 1-2 g after each hemodialysis; maintenance dose as noted above based on Cl",
"     <sub>",
"      cr",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemodiafiltration effects: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mefoxin&reg;: 1 g (50 mL); 2 g (50 mL) [contains sodium 53.8 mg (2.3 mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F147656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Inject deep I.M. into large muscle mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Can be administered IVP over 3-5 minutes at a maximum concentration of 100 mg/mL or I.V. intermittent infusion over 10-60 minutes at a final concentration for I.V. administration not to exceed 40 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS, mannitol 10%, sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, bivalirudin, cyclosporine, cyclophosphamide, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, etoposide phosphate, famotidine, fluconazole, foscarnet, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, linezolid, magnesium sulfate, meperidine, morphine, multivitamins, ondansetron, oxytocin, propofol, ranitidine, remifentanil, teniposide, thiotepa.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Anakinra, fenoldopam, filgrastim, hetastarch in NS, pantoprazole, pemetrexed, pentamidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Less active against staphylococci and streptococci than first generation cephalosporins, but active against anaerobes including",
"     <i>",
"      Bacteroides fragilis",
"     </i>",
"     ; active against gram-negative enteric bacilli including",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     , and",
"     <i>",
"      Proteus",
"     </i>",
"     ; used predominantly for respiratory tract, skin, bone and joint, urinary tract and gynecologic infections as well as septicemia; surgical prophylaxis; intra-abdominal infections and other mixed infections; indicated for bacterial",
"     <i>",
"      Eikenella corrodens",
"     </i>",
"     infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CefOXitin may be confused with ceFAZolin, cefotaxime, cefoTEtan, cefTAZidime, cefTRIAXone, Cytoxan",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mefoxin&reg; may be confused with Lanoxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, bone marrow suppression, BUN increased, creatinine increased, dyspnea, eosinophilia, exacerbation of myasthenia gravis, exfoliative dermatitis, fever, hemolytic anemia, hypotension, interstitial nephritis, jaundice, leukopenia, nausea, nephrotoxicity (with aminoglycosides), phlebitis, prolonged PT, pruritus, pseudomembranous colitis, rash, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, transaminases increased, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, cholestasis, colitis, erythema multiforme, hemolytic anemia, hemorrhage, pancytopenia, renal dysfunction, seizure, serum-sickness reactions, Stevens-Johnson syndrome, superinfection, toxic nephropathy, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5953484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Peak serum concentrations of cefoxitin during pregnancy may be similar to or decreased compared to nonpregnant values. Maternal half-life may be shorter at term. Pregnancy-induced hypertension increases trough concentrations in the immediate postpartum period. Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F147661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of cefoxitin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefoxitin to nursing women. Nondose-related effects could include modification of bowel flora. Cefoxitin pharmacokinetics may be altered immediately postpartum.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F147662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Mefoxin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2 gm/50 mL (50 mL): $10.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1.1 gm/50 mL (50 mL): $19.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefOXitin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $112.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefOXitin Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $11.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $22.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CefOXitin Sodium-Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g 4% (1): $12.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g 2.2% (1): $22.56",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function periodically when used in combination with other nephrotoxic drugs; prothrombin time. Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cefaxicina (ES);",
"     </li>",
"     <li>",
"      Cefmore (TW);",
"     </li>",
"     <li>",
"      Cefoxitin Sodium (AU);",
"     </li>",
"     <li>",
"      Cefoxivit (PH);",
"     </li>",
"     <li>",
"      Cefoxona (AR);",
"     </li>",
"     <li>",
"      Cefxitin (TH);",
"     </li>",
"     <li>",
"      Cenomycin (JP);",
"     </li>",
"     <li>",
"      Daliding (CL);",
"     </li>",
"     <li>",
"      Dintaxin (PH);",
"     </li>",
"     <li>",
"      Gamacef (BR);",
"     </li>",
"     <li>",
"      Jeitin (KP);",
"     </li>",
"     <li>",
"      Lofatin (TW);",
"     </li>",
"     <li>",
"      Mefoxil (GR);",
"     </li>",
"     <li>",
"      Mefoxin (AE, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CI, CY, CZ, EG, ET, FI, FR, GB, GH, GM, GN, GY, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, NZ, OM, PT, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Mefoxitin (AT, CH, DE, DK, ES, NO, SE, VE);",
"     </li>",
"     <li>",
"      Merxin (JP);",
"     </li>",
"     <li>",
"      Monowel (PH);",
"     </li>",
"     <li>",
"      Pacetin (PH);",
"     </li>",
"     <li>",
"      Panafox (PH);",
"     </li>",
"     <li>",
"      Sephros (MY);",
"     </li>",
"     <li>",
"      Voxitin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zepax (PH);",
"     </li>",
"     <li>",
"      Zepotin (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely to body tissues and fluids including pleural, synovial, ascitic, bile; poorly penetrates into CSF even with inflammation of the meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65% to 79%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 45-60 minutes; significantly prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (85% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(906):91-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/8371696/pubmed\" id=\"8371696\" target=\"_blank\">",
"        8371696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al, &ldquo;Antimicrobial Prophylaxis for Surgery: An Advisory Statement From the National Surgical Infection Prevention Project,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 38(12):1706-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/15227616/pubmed\" id=\"15227616\" target=\"_blank\">",
"        15227616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2006, 55(RR-11): 1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/16760892/pubmed\" id=\"16760892\" target=\"_blank\">",
"        16760892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman WE, Moffitt S, and Sprow N, &ldquo;Clinical and Pharmacokinetic Evaluation of Parenteral Cefoxitin in Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1980, 17(4):669-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/7396456/pubmed\" id=\"7396456\" target=\"_blank\">",
"        7396456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia MJ, Garcia A, Nieto MJ, et al, &ldquo;Disposition of Cefoxitin in the Elderly,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1980, 18(11):503-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/7203727/pubmed\" id=\"7203727\" target=\"_blank\">",
"        7203727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Regazzi MB, Chirico G, Cristiani D, et al, &ldquo;Cefoxitin in Newborn Infants. A Clinical and Pharmacokinetic Study,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1983, 25(4):507-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/6653646/pubmed\" id=\"6653646\" target=\"_blank\">",
"        6653646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11094/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9223 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11094=[""].join("\n");
var outline_f10_53_11094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327785\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965749\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147719\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147677\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147699\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147678\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147679\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682542\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147652\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147636\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147656\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147724\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147655\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147726\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147717\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147659\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147640\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298992\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147645\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147648\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5953484\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147683\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147661\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147662\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323049\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147650\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038555\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147639\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147658\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/35/564?source=related_link\">",
"      Cefoxitin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=related_link\">",
"      Cefoxitin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_53_11095="Ureteral stent placement";
var content_f10_53_11095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Ureteral stent placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 661px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ureteral orifice is first identified (A), and cannulated with a guidewire (B). The guidewire is placed beyond the area of obstruction and into the renal pelvis (C). A ureteral access catheter is placed over the guidewire, the guidewire is removed and contrast is injected to opacify the renal pelvis aiding accurate stent placement (D). The guidewire is replaced into the renal pelvis through the access catheter, which is then removed (not shown). The red metal-tipped pusher is used to maneuver the stent over the wire and up the ureter (E). The end of the ureteral stent can be seen at the bladder neck. Finally, the wire is removed and the stent is fully deployed (F). A full pigtail curl should be visualized in the bladder. Fluoroscopy can also be used to verify an adequate curl in the renal pelvis (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sutchin Patel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11095=[""].join("\n");
var outline_f10_53_11095=null;
var title_f10_53_11096="Dextroamphetamine and amphetamine: Pediatric drug information";
var content_f10_53_11096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextroamphetamine and amphetamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/41/44695?source=see_link\">",
"    see \"Dextroamphetamine and amphetamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/12/33989?source=see_link\">",
"    see \"Dextroamphetamine and amphetamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adderall XR&reg;;",
"     </li>",
"     <li>",
"      Adderall&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F935382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adderall XR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amphetamine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anorexiant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/41/44695?source=see_link\">",
"      see \"Dextroamphetamine and amphetamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest effective individualized dose; administer first dose as soon as awake",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 3-5 years: Oral: Initial 2.5 mg daily given every morning; increase daily dose by 2.5 mg at weekly intervals until optimal response is obtained; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"     given in 1-2 divided doses per day; use intervals of 4-6 hours between doses.",
"     <b>",
"      Note:",
"     </b>",
"     Select patients may require daily dose to be given in 3 divided doses per day. Although FDA approved, current guidelines do not recommend dextroamphetamine/amphetamine use in children &le;5 years due to insufficient evidence (AAP, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents: Oral: Initial: 5 mg once or twice daily; increase daily dose by 5 mg at weekly intervals until optimal response is obtained; usual maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"     given in 1-2 divided doses per day; use intervals of 4-6 hours between doses; in patients &gt;50 kg a maximum daily dose of 60 mg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses has been used (Dopheide, 2009; Pliszka, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Select patients may require daily dose to be given in 3 divided doses per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release capsules:",
"     <b>",
"      Note:",
"     </b>",
"     Patients taking divided doses of immediate release tablets may be switched to extended release capsule using the same total daily dose (taken once daily); titrate dose at weekly intervals to achieve optimal response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-12 years: Oral: Initial: 5-10 mg daily given every morning; increase daily dose by 5 mg or 10 mg at weekly intervals until optimal response is obtained; usual maximum daily dose: 30 mg/",
"     <b>",
"      day",
"     </b>",
"     ; in patients &gt;50 kg a maximum daily dose of 60 mg/",
"     <b>",
"      day",
"     </b>",
"     has been used (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents 13-17 years: Oral: Initial: 10 mg daily given every morning; may increase to 20 mg daily after 1 week if symptoms are not controlled; usual maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; in patients &gt;50 kg a maximum daily dose of 60 mg/",
"     <b>",
"      day",
"     </b>",
"     has been used (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: Immediate release tablets: Oral: Initial: 5 mg daily; increase daily dose by 5 mg at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     given in 1-3 divided doses per day; use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Immediate release tablets: Oral: Initial: 10 mg daily; increase daily dose by 10 mg at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     given in 1-3 divided doses per day; use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release tablets: Oral: Initial: 5 mg once or twice daily; increase daily dose in 5 mg increments at weekly intervals until optimal response is obtained; usual maximum dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"     given in 1-3 divided doses per day; use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release capsules: Oral: Initial: 20 mg once daily in the  morning;  higher doses (up to 60 mg once daily) have been evaluated; however, there is not adequate evidence that higher doses provide additional benefit.",
"     <b>",
"      Note:",
"     </b>",
"     Patients taking divided doses of immediate release tablets may be switched to extended release capsule using the same total daily dose (taken once daily); titrate dose at weekly intervals to achieve optimal response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Immediate release tablets: Oral: Initial: 10 mg daily; increase daily dose by 10 mg at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     given in 1-3 divided doses per day; use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustments provided in the manufacturer's labeling; use with caution; elimination may be decreased with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustments provided in the manufacturer's labeling; use with caution; elimination may be decreased with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.1 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.5 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg [dextroamphetamine sulfate 6.25 mg, dextroamphetamine saccharate 6.25 mg, amphetamine aspartate monohydrate 6.25 mg, amphetamine sulfate 6.25 mg (equivalent to amphetamine base 15.6 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adderall XR&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.1 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.5 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25 mg [dextroamphetamine sulfate 6.25 mg, dextroamphetamine saccharate 6.25 mg, amphetamine aspartate monohydrate 6.25 mg, amphetamine sulfate 6.25 mg (equivalent to amphetamine base 15.6 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.13 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg [dextroamphetamine 1.875 mg, dextroamphetamine saccharate 1.875 mg, amphetamine aspartate monohydrate 1.875 mg, amphetamine sulfate 1.875 mg (equivalent to amphetamine base 4.7 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg [dextroamphetamine sulfate 3.125 mg, dextroamphetamine saccharate 3.125 mg, amphetamine aspartate monohydrate 3.125 mg, amphetamine sulfate 3.125 mg (equivalent to amphetamine base 7.8 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.6 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adderall&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5 mg [dextroamphetamine sulfate 1.25 mg, dextroamphetamine saccharate 1.25 mg, amphetamine aspartate monohydrate 1.25 mg, amphetamine sulfate 1.25 mg (equivalent to amphetamine base 3.13 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7.5 mg [dextroamphetamine sulfate 1.875 mg, dextroamphetamine saccharate 1.875 mg, amphetamine aspartate monohydrate 1.875 mg, amphetamine sulfate 1.875 mg (equivalent to amphetamine base 4.7 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 mg [dextroamphetamine sulfate 2.5 mg, dextroamphetamine saccharate 2.5 mg, amphetamine aspartate monohydrate 2.5 mg, amphetamine sulfate 2.5 mg (equivalent to amphetamine base 6.3 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12.5 mg [dextroamphetamine sulfate 3.125 mg, dextroamphetamine saccharate 3.125 mg, amphetamine aspartate monohydrate 3.125 mg, amphetamine sulfate 3.125 mg (equivalent to amphetamine base 7.8 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15 mg [dextroamphetamine sulfate 3.75 mg, dextroamphetamine saccharate 3.75 mg, amphetamine aspartate monohydrate 3.75 mg, amphetamine sulfate 3.75 mg (equivalent to amphetamine base 9.4 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 mg [dextroamphetamine sulfate 5 mg, dextroamphetamine saccharate 5 mg, amphetamine aspartate monohydrate 5 mg, amphetamine sulfate 5 mg (equivalent to amphetamine base 12.6 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     30 mg [dextroamphetamine sulfate 7.5 mg, dextroamphetamine saccharate 7.5 mg, amphetamine aspartate monohydrate 7.5 mg, amphetamine sulfate 7.5 mg (equivalent to amphetamine base 18.8 mg)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F158747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085819.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085819.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablet: To avoid insomnia, last daily dose should be administered no less than 6 hours before retiring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release capsule: Avoid afternoon doses to prevent insomnia. Swallow capsule whole; do not chew or divide. May be administered with or without food. May open capsule and sprinkle contents on applesauce; consume applesauce/medication mixture immediately; do not store; do not chew sprinkled beads from capsule",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets (Adderall&reg;): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in tight, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release capsules (Adderall XR&reg;): Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in tight, light-resistant container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets (Adderall&reg;): Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;3 years and adults); treatment of narcolepsy (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release capsules (Adderall XR&reg;): Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Adderall&reg; may be confused with Inderal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F158750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      As reported with Adderall XR&reg;:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, dizziness, emotional lability, fever, headache, insomnia, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, impotence, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, infection, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, anaphylaxis, angioedema, anorexia, blurred vision, cardiomyopathy, depression, dyskinesia, dysphoria, euphoria, hypertension, MI, mydriasis, psychosis, rash, seizure, stroke, sudden death, teeth clenching, tics, tooth infection, Tourette's syndrome, tremor, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to dextroamphetamine, amphetamine, sympathomimetic amines, or any component; advanced arteriosclerosis, moderate to severe hypertension, symptomatic cardiovascular disease, hyperthyroidism, glaucoma, agitated states, history of drug abuse; concurrent use or use within 14 days of MAO inhibitors (hypertensive crisis may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving other sympathomimetic agents. Prescribe or dispense least amount feasible to minimize chance of overdose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious cardiovascular events including sudden death may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of amphetamines in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of amphetamines. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as dextroamphetamine and amphetamine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009). In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low  (Cooper, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Stimulant medications may increase blood pressure (average increase 2-4 mm Hg) and heart rate (average increase 3-6 bpm); some patients may experience greater increases; use stimulant medications with caution in patients with hypertension and other cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate. Use is contraindicated in patients with moderate to severe hypertension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psychiatric adverse events may occur. Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients without a prior history of psychotic illness or mania, even at standard doses. Stimulants may induce mixed/manic episode in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children. Stimulants may lower seizure threshold leading to new onset or breakthrough seizure activity; use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amphetamines possess a high potential for abuse",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; misuse may cause sudden death and serious cardiovascular adverse events",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; prolonged administration may lead to drug dependence; abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal; avoid abrupt discontinuation in patients who have received amphetamines for prolonged periods. Amphetamines may impair the ability to engage in potentially hazardous activities. May exacerbate motor and phonic tics and Tourette's syndrome. Visual disturbances (difficulty in accommodation and blurred vision) have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F158739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acidic foods, juices, or vitamin C may decrease oral absorption",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Extended release capsules: Food does not affect the extent of absorption; a high-fat meal delays the time to peak concentration of d-amphetamine by 2.5 hours and l-amphetamine by 2.1 hours; similar absorption occurs if capsule is opened and contents sprinkled on applesauce versus swallowing intact capsule on an empty stomach",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity, blood pressure, heart rate, sleep, appetite, abnormal movements, height, weight, BMI, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression. Monitor for visual disturbances.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amphetamines are noncatecholamine, sympathomimetic amines that promote the release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals, thus increasing the amounts of circulating dopamine and norepinephrine in the cerebral cortex and reticular activating system. A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition. Amphetamines also weakly inhibit the action of monoamine oxidase. They peripherally increase blood pressure and act as a respiratory stimulant and weak bronchodilator.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Tablet: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Tablet: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.5-4.6 L/kg; distributes into CNS, mean CSF concentrations are 80% of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via cytochrome P450 mono-oxygenase and glucuronidation; two active metabolites (norephedrine and 4-hydroxyamphetamine) are formed via oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     d-amphetamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents 13-17 years: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     l-amphetamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents 13-17 years: 13-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet (immediate release): 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule (extended release): 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 70% of a single dose is eliminated within 24 hours; excreted as unchanged amphetamine (30%), benzoic acid, hydroxyamphetamine, hippuric acid, norephedrine and p-hydroxynorephedrine;",
"     <b>",
"      Note:",
"     </b>",
"     Urinary recovery of amphetamine is highly dependent on urine flow rates and urinary pH; urinary recovery of amphetamine may range from 1% in alkaline urine to 75% in acidic urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Children have a higher clearance (on a mg/kg basis) than adolescents and adults",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/12/33989?source=see_link\">",
"      see \"Dextroamphetamine and amphetamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of dextroamphetamine and amphetamine. Serious cardiac effects or psychiatric adverse effects may occur; notify physician of any heart problems, high blood pressure, or psychiatric conditions before starting therapy. May reduce the growth rate in children and has been associated with worsening of aggressive behavior; notify physician if child displays aggression or hostility. Ensure that physician monitors child&rsquo;s weight and height. May impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use. Limit caffeine; avoid alcohol and the herbal medicine St John's wort. May cause dry mouth. Notify physician if blurred vision occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of ADHD should include &ldquo;drug holidays&rdquo; or periodic discontinuation of medication in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures. The combination of equal parts of",
"     <i>",
"      d",
"     </i>",
"     ,",
"     <i>",
"      l",
"     </i>",
"     -amphetamine aspartate,",
"     <i>",
"      d",
"     </i>",
"     ,",
"     <i>",
"      l",
"     </i>",
"     -amphetamine sulfate, dextroamphetamine saccharate and dextroamphetamine sulfate results in a 3:1 ratio of the dextro- and levo-isomers of amphetamine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The duration of action of Adderall&reg; is longer than methylphenidate; behavioral effects of a single morning dose of Adderall&reg; may last throughout the school day; a single morning dose of Adderall&reg; has been shown in several studies to be as effective as twice daily dosing of methylphenidate for the treatment of ADHD (Manos, 1999; Pelham, 1999; Pliszka, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10950991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets. Crush ten 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of Ora-Sweet&reg; and mix to a uniform paste; mix while adding the vehicle in equal proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label \"shake well\". Stable 30 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Justice J, Kupiec TC, Matthews P, et al, \"Stability of Adderall in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2001, 58(15):1418-21.",
"     <span class=\"pubmed-id\">",
"      11494787",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women, \"Committee Opinion No. 479: Methamphetamine Abuse in Women of Reproductive Age,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):751-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/21343793/pubmed\" id=\"21343793\" target=\"_blank\">",
"        21343793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, \"ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA and Pliszka SR, \"Attention-Deficit-Hyperactivity Disorder: An Update,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(6):656-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/19476419/pubmed\" id=\"19476419\" target=\"_blank\">",
"        19476419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Golub M, Costa L, Crofton K, et al, \"NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Amphetamine and Methamphetamine,\"",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2005, 74(6):471-584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/16167346/pubmed\" id=\"16167346\" target=\"_blank\">",
"        16167346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaGasse LL, Derauf C, Smith LM, et al, \"Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(4):681-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/22430455/pubmed\" id=\"22430455\" target=\"_blank\">",
"        22430455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manos MJ, Short EJ, and Findling RL, &ldquo;Differential Effectiveness of Methylphenidate and Adderall&reg; in School-Age Youths With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(7):813-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/10405498/pubmed\" id=\"10405498\" target=\"_blank\">",
"        10405498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelham WE, Gnagy EM, Chronis AM, et al, \"A Comparison of Morning-Only and Morning/Late Afternoon Adderall to Morning-Only, Twice-Daily, and Three Times-Daily Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(6):1300-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/10585981/pubmed\" id=\"10585981\" target=\"_blank\">",
"        10585981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka SR, Browne RG, Olvera RL, et al, &ldquo;A Double-Blind, Placebo-Controlled Study of Adderall&reg; and Methylphenidate in the Treatment of Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 39(5):619-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/10802980/pubmed\" id=\"10802980\" target=\"_blank\">",
"        10802980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steiner E, Vill&eacute;n T, Hallberg M, et al, \"Amphetamine Secretion in Breast Milk,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1984, 27(1):123-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/6489423/pubmed\" id=\"6489423\" target=\"_blank\">",
"        6489423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swanson JM, Wigal S, Greenhill LL, et al, &ldquo;Analog Classroom Assessment of Adderall&reg; in Children With ADHD,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(5):519-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/9585654/pubmed\" id=\"9585654\" target=\"_blank\">",
"        9585654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/53/11096/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13219 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11096=[""].join("\n");
var outline_f10_53_11096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708680\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158728\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F935382\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052100\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052092\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158705\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158688\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158747\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874428\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052105\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052096\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052104\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158753\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158750\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052110\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052091\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052090\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158739\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158697\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052113\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158700\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158713\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052099\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052089\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052108\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052109\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052098\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052111\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10950991\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/41/44695?source=related_link\">",
"      Dextroamphetamine and amphetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/12/33989?source=related_link\">",
"      Dextroamphetamine and amphetamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_53_11097="Arterial switch operation";
var content_f10_53_11097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Arterial switch operation for transposition of the great arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical technique of the arterial switch operation.",
"    <br>",
"     (A) Aortic cannula is positioned distally in the ascending aorta, the ductus arteriosus is divided between suture ligatures, and the branch pulmonary arteries are dissected out to the hilum to provide adequate mobility for anterior translocation. The broken lines represent the levels of transection of the aorta and the main pulmonary artery. Marking sutures are placed in the anticipated sites of coronary transfer.",
"     <br>",
"      (B) Transection of the great arteries. The left ventricular outflow tract, neoaortic valve, and coronary arteries are thoroughly inspected.",
"      <br>",
"       (C) The coronary arterial buttons are excised from the free edge of the aorta to the base of the sinus of Valsalva.",
"       <br>",
"        (D) The coronary buttons are anastomosed to V-shaped excisions made in the neoaorta.",
"        <br>",
"         (E) The pulmonary artery is brought anterior to the aorta (Lecompte maneuver). Anastomosis of the proximal neoaorta is shown.",
"         <br>",
"          (F) The coronary donor sites are filled with autologous pericardial patches. A single U-shaped patch (F) or two separate patches (G) may be used.",
"          <br>",
"           (H) Anastomosis of the proximal neopulmonary artery and the distal pulmonary artery.",
"           <div class=\"footnotes\">",
"           </div>",
"           <div class=\"reference\">",
"            Reproduced from: Castaneda AR. Anatomic correction of the transposition of the great arteries at the arterial level. In: Surgery of the Chest, Sabiston DC Jr, Spencer FC (Eds), WB Saunders, Philadelphia 1990. Illustrations used with the permission of Elsevier Inc. All rights reserved.",
"           </div>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11097=[""].join("\n");
var outline_f10_53_11097=null;
var title_f10_53_11098="Beta blockers in the management of acute coronary syndrome";
var content_f10_53_11098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta blockers in the management of acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Harold L Kennedy, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/53/11098/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/53/11098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are an essential component of the management of patients with acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potentially beneficial effects of beta blockers in this setting include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased oxygen demand due to the reductions in heart rate, blood pressure, and contractility, and the consequent relief of ischemic chest pain.",
"     </li>",
"     <li>",
"      Decreased risk of ventricular fibrillation as suggested by experimental studies demonstrating an increase in the ventricular fibrillation threshold and by clinical trials showing a relative risk reduction in sudden cardiac death (eg, 30 to 47 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased automaticity, increased electrophysiologic threshold for activation, and slowing of conduction.",
"     </li>",
"     <li>",
"      Bradycardia prolongs diastole and therefore improves coronary diastolic perfusion and reduces afterdepolarizations and triggered activity.",
"     </li>",
"     <li>",
"      Reduction in remodeling and improvement in left ventricular hemodynamic function, depending upon infarct size and the timing of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=see_link\">",
"       \"Cardiac remodeling: Clinical assessment and therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Improved left ventricular diastolic function with a less restrictive filling pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"       \"Treatment and prognosis of diastolic heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Slowing of the yearly rate of progression of coronary atherosclerosis in patients with and without MI, as demonstrated by intravascular ultrasound evaluation of atheroma volume [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy and clinical use of beta blockers in acute MI will be discussed here. The general characteristics of beta blockers are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overall benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of a beta blocker following an acute MI reduced morbidity and mortality in multiple trials. Studies in the prefibrinolysis era showed a mortality benefit of 10 to 15 percent in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef80761 \" href=\"UTD.htm?23/13/23774\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/10-15\">",
"     10-15",
"    </a>",
"    ] and early intravenous therapy was associated with a reduction in infarct size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/10\">",
"     10",
"    </a>",
"    ]. These observations should apply to current patients who are not treated with reperfusion or revascularization.",
"   </p>",
"   <p>",
"    The benefits of beta blockade have been confirmed in the reperfusion era with up to a 40 percent reduction in mortality in those with an ST elevation (Q wave) or non-ST elevation (non-Q wave) MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In a systematic review published in 1999, the overall mortality in all patients randomly assigned to beta blockers or placebo in 31 long-term trials that included almost 25,000 patients was 10.1 percent; beta blockers reduced the odds of death by 23 percent (95% CI 15-31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/17\">",
"     17",
"    </a>",
"    ]. Older adults derive similar or greater benefit with beta blockers at the time of MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality benefit is in part due to a lower rate of sudden cardiac death (SCD). In a review of 13 trials that reported data on SCD, the average incidence was reduced from 5.0 to 3.3 percent (relative risk reduction 30 to 47 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/3\">",
"     3",
"    </a>",
"    ]. A similar reduction in SCD was noted in the largest of these trials (4.6 to 3.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of beta blocker therapy may vary among patients. One possible determinant of response is specific polymorphisms in the gene for the beta-2 adrenergic receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patients who undergo reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized, placebo controlled trials in patients treated with fibrinolytic therapy or percutaneous coronary intervention have often compared early and deferred beta blocker therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. There is no clear evidence of a mortality benefit from early intervention in randomized trials in these patients, as most supportive data have come from retrospective analyses.",
"   </p>",
"   <p>",
"    In a retrospective review of over 200,000 patients from the Cooperative Cardiovascular Project, a significantly lower mortality was observed in the 15 percent of patients treated with fibrinolytic therapy (11.8 versus 19.6 percent, relative risk 0.60) who received beta blocker therapy at the time of discharge (",
"    <a class=\"graphic graphic_figure graphicRef79592 \" href=\"UTD.htm?16/50/17198\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings were somewhat different in the randomized",
"    <span class=\"nowrap\">",
"     COMMIT/CCS2",
"    </span>",
"    trial of almost 46,000 patients (93 percent with ST elevation or left bundle branch block), one-half of whom received fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/24\">",
"     24",
"    </a>",
"    ]. There was no overall mortality benefit from early intravenous beta blocker therapy. However, hemodynamic stability appeared to be an important determinant of the response to beta blockers. There was a significant increase in mortality in patients who presented with hemodynamic compromise that was balanced by a trend toward reduced mortality in patients who were hemodynamically stable. Importantly, patients with hemodynamic compromise and who received beta blockers did not go through a period of uptitration of the drug. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Early administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The increase in risk in hemodynamically compromised patients is consistent with current recommendations from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    that beta blockers are relatively contraindicated in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational analyses conducted within the context of randomized trials suggest that beta blockers are also beneficial in patients undergoing primary PCI, and should be administered intravenously",
"    <strong>",
"     before",
"    </strong>",
"    PCI as well as orally after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/27\">",
"     27",
"    </a>",
"    ]. An apparent benefit from preprocedural intravenous administration of a beta blocker was shown in a retrospective analysis from the CADILLAC trial of 2082 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/28\">",
"     28",
"    </a>",
"    ]. At 30 days, patients who had received a preprocedural beta blocker had a significantly lower mortality than those who had not (1.5 versus 2.8 percent); the lower mortality was limited to patients who had not been receiving an oral beta blocker before admission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although early administration before PCI is recommended, lower mortality has also been seen when beta blocker therapy is begun after primary PCI. This was illustrated in an analysis of 2442 patients who underwent successful primary PCI: 1661 received a beta blocker after PCI (68 percent) and 781 did not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/29\">",
"     29",
"    </a>",
"    ]. At six months, post-PCI beta blockers were associated with a significant lower mortality (2.2 versus 6.6 percent, adjusted odds ratio 0.43).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patients treated with antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are effective in patients treated with antiarrhythmic drugs (",
"    <a class=\"graphic graphic_figure graphicRef70258 \" href=\"UTD.htm?29/22/30062\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58963 \" href=\"UTD.htm?18/16/18701\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/16,30,31\">",
"     16,30,31",
"    </a>",
"    ]. This was illustrated in a pooled analysis of patients in the CAMIAT and EMIAT trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/31\">",
"     31",
"    </a>",
"    ]. The relative risks for all-cause mortality, cardiac death, arrhythmic deaths, and resuscitated cardiac arrest were lower for patients receiving beta blockers along with amiodarone than for those without a beta blocker, with or without amiodarone. This interaction was significant for cardiac death and for arrhythmic death or resuscitated cardiac arrest (relative risk 0.59 and 0.39) (",
"    <a class=\"graphic graphic_figure graphicRef68950 graphicRef55671 \" href=\"UTD.htm?26/49/27423\">",
"     figure 5A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/31\">",
"     31",
"    </a>",
"    ]. Antiarrhythmic drugs other than amiodarone have not been similarly studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patients with potential contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survival benefit from beta blockade is also seen in patients with potential contraindications to such therapy such as chronic obstructive pulmonary disease",
"    <span class=\"nowrap\">",
"     (COPD)/asthma,",
"    </span>",
"    reduced left ventricular ejection fraction, overt heart failure, diabetes mellitus, and peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/23,32-39\">",
"     23,32-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     COPD/asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are safe and effective in patients with mild pulmonary disease as illustrated by the following data from observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nonrandomized observational study of 54,962 MI patients over the age of 65 years who had no contraindications to beta blocker therapy, beta blockers were associated with a lower one year mortality in patients with COPD or asthma who were not on beta agonist therapy (adjusted relative risk 0.85 compared to no beta blockers); the lower mortality was similar to that seen in patients without COPD or asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/35\">",
"       35",
"      </a>",
"      ]. In contrast, beta blockers had no difference in survival in patients who were using a beta agonist or who had severe COPD or asthma.",
"     </li>",
"     <li>",
"      A similar apparent benefit was noted in a review of over 200,000 MI patients from the Cooperative Cardiovascular Project [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/23\">",
"       23",
"      </a>",
"      ]. At two years, survival among patients with COPD was significantly higher in those treated with a beta blocker (83 versus 72 percent without a beta blocker) (",
"      <a class=\"graphic graphic_figure graphicRef54684 \" href=\"UTD.htm?30/61/31709\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a review of randomized trials which studied the effect of beta blockers on parameters of pulmonary function in patients with mild to moderate reactive airway disease, cardioselective agents did not produce adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blocker therapy is associated with reduced mortality in exacerbations of COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/41,42\">",
"       41,42",
"      </a>",
"      ], and reduces exacerbations when added to established inhaled stepwise therapy for COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/42\">",
"       42",
"      </a>",
"      ]. The latter study indicated that beta blocker therapy was independent of overt cardiovascular disease and cardiac drugs, and without adverse effects on pulmonary FEV1&nbsp;function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients are not treated with a beta blocker because of presumed COPD that has not been confirmed. In one report, only 15 of 94 patients with an acute coronary syndrome and a diagnosis of COPD were treated with a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/43\">",
"     43",
"    </a>",
"    ]. However, 36 patients (38 percent) had never been seen by a chest physician nor had previous pulmonary function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     LV dysfunction/heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of beta blockers in post-MI patients in the trials described above were performed before the availability of ACE inhibitors and did not assess patients with asymptomatic left ventricular (LV) dysfunction or heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/12,14,15\">",
"     12,14,15",
"    </a>",
"    ]. They were also performed before the beneficial effects of beta blockers in heart failure were demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence to support the concomitant use of beta blockers and angiotensin inhibition in patients with MI complicated by either LV systolic dysfunction or heart failure comes from observational studies and one randomized trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retrospective analyses of data from ACE inhibitor trials, SAVE and SOLVD-prevention trials of patients with asymptomatic left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/36,37\">",
"       36,37",
"      </a>",
"      ] and the AIRE trial of patients with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/32\">",
"       32",
"      </a>",
"      ], suggest that those patients who were treated with a beta blocker had lower rates of cardiovascular events than those not receiving a beta blocker (",
"      <a class=\"graphic graphic_figure graphicRef67944 \" href=\"UTD.htm?30/42/31405\">",
"       figure 7",
"      </a>",
"      ). A lower mortality rate with beta blockers was also noted in the review from the Cooperative Cardiovascular Project mentioned above; this effect was seen in patients with a left ventricular ejection fraction between 20 and 49 percent and below 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a retrospective analysis of the more contemporary VALIANT trial of 14,703 patients with MI complicated by either LV systolic dysfunction or heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H17#H17\">",
"       \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Comparison to ACE inhibitor'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The three year mortality was significantly lower in those treated with beta blockers either before or after randomization, or both, compared to those who were not (31, 26, 18, and 35 percent, respectively).",
"     </li>",
"     <li>",
"      The effect of beta blockers in patients with left ventricular dysfunction was more directly addressed in the CAPRICORN trial in which almost 2000 patients with a left ventricular ejection fraction &le;40 percent (mean 33 percent) after an acute MI were treated with an ACE inhibitor and randomly assigned to placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      (6.25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      initially and then progressively increased during the next four to six weeks to a maximum of 25 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/33\">",
"       33",
"      </a>",
"      ]. At a mean follow-up of 1.3 years, carvedilol did not reduce the primary combined end point of all-cause mortality or hospitalization for cardiovascular problems (35 versus 37 percent); however, there were significant reductions in all-cause mortality alone (12 versus 15 percent, hazard ratio 0.77, 95% CI 0.60-0.98) and the secondary end point of nonfatal MI (3 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern about the possibility of masking hypoglycemic symptoms or worsening glycemic control has made some physicians reluctant to prescribe beta blockers to patients with diabetes during an acute MI. However, these concerns have been overstated, and analysis of outcomes of diabetic subgroups in several postinfarction beta blocker trials documents an overall benefit from the use of beta blockers that is at least equivalent to and may be greater than that seen in patients without diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of acute myocardial infarction in diabetes mellitus\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there has been a concern involving the use of beta blockers in patients with intermittent claudication, there appears to be no adverse effect of beta-1 selective blockers on claudication symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The use of beta blockers in patients with peripheral artery disease, including abdominal aortic aneurysm, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MODES OF ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an acute MI, beta blockers can be given early (within four to six hours of presentation) or late (beyond this time). Therapy can be instituted in all patients or selectively in those at increased risk. Most patients are treated",
"    <strong>",
"     indefinitely",
"    </strong>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Early administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous beta blockers, as compared with oral therapy, has been evaluated predominantly in patients with ST elevation MI. Early intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    are best studied and of proven safety. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    , which has a short half-life of 8 to 10 minutes, can be given to test the response to beta blockade in patients who are at increased risk for hemodynamic compromise, although this approach is rarely used in practice.",
"   </p>",
"   <p>",
"    Pooled data from controlled trials involving over 29,000 patients undergoing early, short-term IV administration of a beta blocker showed a 13 percent relative risk reduction in acute mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/16\">",
"     16",
"    </a>",
"    ]. In ISIS-1, performed in the prefibrinolysis era, early IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    followed by oral therapy for one week resulted in a significant reduction in mortality at one week (3.9 versus 4.6 percent) and one year (10.7 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/15\">",
"     15",
"    </a>",
"    ]. Almost all of the reduction in mortality with atenolol occurred on the day of admission or the subsequent day, and much of the difference was due to a lower rate of left ventricular free wall rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/47\">",
"     47",
"    </a>",
"    ]. It was estimated that the administration of atenolol to 200 patients would prevent one reinfarction, one arrest, and one death in the first week.",
"   </p>",
"   <p>",
"    Although early IV beta blockade has become an accepted ancillary therapy in many patients undergoing fibrinolytic therapy for MI, there is no convincing evidence of a mortality benefit. This issue was directly addressed in the",
"    <span class=\"nowrap\">",
"     COMMIT/CCS2",
"    </span>",
"    trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/24\">",
"     24",
"    </a>",
"    ]. In this trial, 45,582 patients with an acute ST MI (93 percent with ST elevation or left bundle branch block, one-half of whom received fibrinolytic therapy) were randomly assigned to placebo or to three 5 mg intravenous boluses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    tartrate followed by oral metoprolol extended release (succinate) 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 30 days. The primary end points were death and the composite of death, repeat MI, or stroke during the initial hospitalization (or at a maximum of 40 days). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in mortality between the two groups (7.8 versus 7.8 percent with placebo).",
"     </li>",
"     <li>",
"      There was an increase in mortality in patients who presented with hemodynamic compromise that was balanced by a trend toward reduced mortality in patients who were hemodynamically stable. The increase in mortality in the former group may have been attributable to a 30 percent relative increase in cardiogenic shock.",
"     </li>",
"     <li>",
"      There was a significantly lower rate of ventricular fibrillation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (2.5 versus 3.9 percent) and reinfarction; these reductions started after day two of admission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of immediate IV beta blockade in patients with hemodynamic instability has been questioned based on this study. The 2008 focused update of the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    STEMI guidelines recommends avoidance of immediate IV beta blockade in these higher risk groups, instead advocating oral beta blockade instituted after day two or hemodynamic stability is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immediate beta blocker therapy may have an additional benefit in patients treated with fibrinolytic therapy, reducing the incidence of intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/21,48\">",
"     21,48",
"    </a>",
"    ]. This effect was suggested in a review of data from 60,329 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    in the National Registry of Myocardial Infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/48\">",
"     48",
"    </a>",
"    ]. Immediate beta blocker use was associated with a lower incidence of intracerebral hemorrhage (0.67 versus 1 percent for no immediate beta blocker; odds ratio 0.69, 95% CI 0.57-0.84). This apparent benefit was seen in all age groups and in both men and women.",
"   </p>",
"   <p>",
"    Beta blockers are also beneficial in patients undergoing primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Beta blockers should be administered before PCI as well as orally after the procedure. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Patients who undergo reperfusion'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not receive a beta blocker during the first 24 hours because of early contraindications should be reevaluated for beta blocker candidacy for subsequent therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardioselective beta blocker, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , is preferred and may be administered as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      tartrate 25 to 50 mg every 6 to 12 hours or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      25 to 50 mg twice daily, initially, titrating upward as needed. Short acting beta blockers are preferred early to allow for more rapid adjustment of dose based on the patient&rsquo;s blood pressure and heart rate response. Near the time of discharge, we prefer to switch to longer acting beta blockers.",
"     </li>",
"     <li>",
"      Patients with hypertension on admission or those needing immediate beta blockade for other reasons, such as atrial fibrillation with rapid ventricular response, may receive IV beta blockade.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      tartrate can be given in 5 mg increments by slow intravenous administration (5 mg over one to two minutes), repeated every five minutes for a total initial dose of 15 mg (three doses). Patients who tolerate this regimen should then receive oral therapy beginning 15 min after the last intravenous dose (25 to 50 mg every six hours for 48 hours of metoprolol tartrate) followed by a maintenance dose of 100 mg twice daily.",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      can be given in a 5 mg dose followed by another 5 mg five minutes later. Patients who tolerate this regimen should then receive oral therapy beginning one to two hours after the last intravenous dose (50 to 100 mg in two divided doses). Intravenous atenolol is not available in the United States or Canada.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       Esmolol",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min increasing to a maximum of 200 to 300",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min), an ultra-short acting beta blocker, can be given to assess tolerance to beta blockade in patients with borderline or questionable left ventricular function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bradycardia and hypotension are the most common limitations to achieving the full dose. In this setting, the rate of administration should be slowed or oral therapy initiated. However, a rigid \"cookbook\" regimen should not be used since there is a variable sympathetic response to acute MI. The goals are to reduce the heart rate to below 70",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    while maintaining a systolic pressure above 90 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Late administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of late beta blockade (more than six hours after presentation) in acute MI have used oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/17\">",
"     17",
"    </a>",
"    ]. Late therapy was associated with a lower rate of mortality as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An overview of results from randomized trials of late beta blocker therapy or placebo in over 24,000 patients found a significant reduction in late-phase mortality (7.5 versus 9.5 percent with placebo, odds ratio 0.77, 95% CI 0.70-0.84) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of outcome of 2877 patients with a first myocardial infarction entered into the Beta Blocker Heart Attack Trial (BHAT) found that the greatest reduction in mortality with late beta blocker therapy (started at a mean of ten days after the MI) occurred in those with persistent ST segment depression from the time of admission to randomization on day 10 (",
"      <a class=\"graphic graphic_figure graphicRef66475 \" href=\"UTD.htm?22/27/22973\">",
"       figure 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not receive a beta blocker during the first 24 hours because of early contraindications should be reevaluated for beta blocker candidacy for subsequent therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;For late oral administration, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the benefit of beta blockers was a class effect and that agents without intrinsic sympathomimetic activity (ISA) were preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/25,26,49\">",
"     25,26,49",
"    </a>",
"    ]. This recommendation is consistent with the findings in a 1999 meta-analysis of randomized controlled trials: there was no significant difference in benefit with cardioselective compared to nonselective drugs, but there was an almost significant trend toward less benefit with drugs that have ISA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in a later trial in which 313 patients with acute anterior MI and a left ventricular ejection &lt;45 percent were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , which is not cardioselective, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/50\">",
"     50",
"    </a>",
"    ]. There was no significant difference between the two groups in time to first composite cardiac adverse event, including all-cause mortality. Higher health-related quality of life scores were noted in the carvedilol group.",
"   </p>",
"   <p>",
"    We suggest use of a beta-1-selective agent in most patients. Usual initial doses are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    tartrate (immediate release preparation) 50 to 100 mg twice daily or metoprolol succinate (extended release preparation) 100 mg daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    50 to 100 mg divided twice daily. We prefer the longer acting preparation. For patients in whom there is a concern for intolerance to these doses, lower initial doses should be used; in this setting up-titration should occur as promptly as possible.",
"   </p>",
"   <p>",
"    Patients with heart failure and systolic left ventricular dysfunction may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , extended-release preparation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients should be continued on an oral beta blocker",
"    <strong>",
"     indefinitely.",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H346544189\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Early versus late administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, early beta blocker therapy is preferred by most clinicians, despite inconclusive evidence supporting this approach. This issue was directly addressed in the TIMI-IIB trial, which randomly assigned 1434 patients with STEMI who were treated with fibrinolysis to either early IV therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    tartrate, 15 mg IV given in three equal doses at two-minute intervals if tolerated, followed by 50 mg orally twice daily for the first day and 100 mg orally twice daily thereafter) or to delayed oral beta blockade (metoprolol, 50 mg twice daily on day six and 100 mg twice daily thereafter) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following benefits of early therapy were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower rate of recurrent chest pain at six days (15.4 versus 21.2 percent).",
"     </li>",
"     <li>",
"      A lower rate of reinfarction at six days (2.7 versus 5.1 percent with later therapy).",
"     </li>",
"     <li>",
"      A significantly lower rate of the combined end point of recurrent MI or death within 21 days (5.0 versus 12.1 percent). However, this benefit was not seen when early IV beta blocker therapy was delayed to two to four hours after the onset of symptoms. There was no difference between the two groups in left ventricular function at hospital discharge and six weeks.",
"     </li>",
"     <li>",
"      A significantly lower total mortality rate at six weeks in the low risk group (0 versus 2.8 percent). No mortality benefit was seen in the \"not low risk\" group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another trial from TIMI II evaluated the efficacy of coronary arteriography 18 to 48 hours after fibrinolytic therapy followed, if appropriate, by percutaneous transluminal coronary angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/22\">",
"     22",
"    </a>",
"    ]. A subset of 1390 patients who were eligible for intravenous beta blockade were randomly assigned to 15 mg of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    tartrate (followed by oral metoprolol) or oral metoprolol begun on day six. There was no significant difference between the two groups in the in-hospital left ventricular ejection fraction or in mortality at 6 and 42 days. However, by day six (just when deferred therapy was started), the early therapy group had, as in TIMI IIb, significant reductions in nonfatal reinfarction (16 versus 31 patients) and recurrent ischemic episodes (107 versus 147 patients).",
"   </p>",
"   <p>",
"    Although the TIMI-II trials were considered too small to detect a difference in overall mortality because of the limited number of events, a similar lack of a significant mortality benefit with early therapy was noted in a meta-analysis and a larger, but nonrandomized, analysis of data from the GUSTO-I trial of fibrinolytic therapy in STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/17,51\">",
"     17,51",
"    </a>",
"    ]. The meta-analysis evaluated 51 short-term and 31 long-term trials that included 54,234 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/17\">",
"     17",
"    </a>",
"    ]. Overall mortality was 10.1 percent. The use of an initial intravenous dose resulted in a nonsignificant reduction in mortality (odds ratio 0.87, 95% CI 0.61-1.22).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Heart rate goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inverse relationship between short-term and long-term mortality and the degree of heart rate reduction with beta blockade after myocardial infarction was suggested in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/52\">",
"     52",
"    </a>",
"    ]. This hypothesis was confirmed in a 2007 meta-regression analysis of 17 trials including nearly 31,000 MI patients who were placed on either a beta blocker (14 trials) or a rate slowing calcium channel blocker (3 trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/53\">",
"     53",
"    </a>",
"    ]. There was a statistically significant and progressive reduction in the odds ratio for all cause and cardiac death and non-fatal MI as the resting heart rate was slowed from 5 to 15",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    compared to baseline. However, the optimal degree of heart rate lowering is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all trials have studied the",
"    <strong>",
"     universal",
"    </strong>",
"    application of beta blockade after MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential contraindications to beta blocker use include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major contraindications include active bronchospasm, severe bradycardia, heart block greater than first degree (unless the patient has a permanent pacemaker), pulmonary edema, and hypotension with or without shock. Such patients should be reevaluated for beta blocker candidacy after they stabilize.",
"     </li>",
"     <li>",
"      Most patients with myocardial infarction precipitated by cocaine use should not be treated with beta blockers because of the risk of precipitating coronary artery spasm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link&amp;anchor=H18#H18\">",
"       \"Evaluation and management of the cardiovascular complications of cocaine abuse\", section on 'Reperfusion and revascularization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Overt heart failure should be brought under medical control prior to the initiation of beta blockade. However, there is a strong indication for carefully initiated oral beta blocker therapy (beginning at very low doses) in such patients prior to discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H8#H8\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Initiation of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concern has been expressed about the use of beta blockers in patients with insulin-dependent diabetes mellitus, COPD, or peripheral artery disease. However, as noted above, beta blockers are beneficial and well tolerated in many such patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patients with potential contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was illustrated in a report in which 94 of 457 patients (21 percent) with an acute coronary syndrome had a diagnosis of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/43\">",
"     43",
"    </a>",
"    ]. Only 15 were treated with a beta blocker. In addition, the diagnosis of COPD was uncertain in many patients, since 36 (38 percent) had never been seen by a chest physician or had previous pulmonary function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although as many as 80 to 90 percent of patients with acute MI are eligible for beta blocker therapy, many patients do not receive such treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/23,55-61\">",
"     23,55-61",
"    </a>",
"    ]. In addition, many treated patients do not receive the recommended dose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/56,61\">",
"     56,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two large multicenter international registries - the Euro Heart Survey of Acute Coronary Syndromes and the Global Registry of Acute Coronary Events (GRACE) - prospectively evaluated the management of over 22,000 patients with an acute coronary syndrome in approximately 200 hospitals (both teaching and nonteaching) around the world from early 1999 through May 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Among the patients with an MI who survived to discharge, a beta blocker was given to 72 to 76 percent.",
"   </p>",
"   <p>",
"    Beta blocker utilization in patients with an acute MI in the United States appears to be improving over time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/18,62\">",
"     18,62",
"    </a>",
"    ]. This was illustrated in a report in which a cohort of Medicare patients hospitalized with acute MI (both STEMI and NSTEMI) between 1994 and 1995 (over 230,000 patients) was compared with a cohort hospitalized between 1998 and 1999 (over 35,000 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/62\">",
"     62",
"    </a>",
"    ]. The use of several recommended therapies increased over time, including early beta blockers (from 51 to 68 percent) and beta blockers at discharge (from 50 to 71 percent).",
"   </p>",
"   <p>",
"    A more recent study from the CRUSADE initiative evaluated beta blocker utilization in over 72,000 NSTEMI patients in the United States between 2001 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/63\">",
"     63",
"    </a>",
"    ]. In patients without contraindications, 83 percent received therapy within 24 hours. Factors associated with use included prior use, stable hemodynamic parameters, and care delivered by a cardiology inpatient service.",
"   </p>",
"   <p>",
"    A variety of factors have contributed to the underutilization of beta blockers after acute MI. These include misinformation, exaggerated concern for adverse effects, outdated knowledge of contraindications to beta blocker therapy, and competitive misinformation from pharmaceutical companies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/55,60\">",
"     55,60",
"    </a>",
"    ]. Patients not begun on a beta blocker in the hospital or shortly after discharge are unlikely to be started on such therapy at a later time (9 to 12 percent at one year in two reports) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/61,64\">",
"     61,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another problem with utilization is that patients who are started on a beta blocker do not necessarily continue to take the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/61,64\">",
"     61,64",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a report from a national registry from Denmark of over 55,000 patients with a first MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/61\">",
"     61",
"    </a>",
"    ]. The rate of continued beta blocker therapy in survivors who started such therapy was 78, 64, and 58 percent at one, three, and five years. In another series, the progressive decline over time was similar in patients thought to be \"ideal\" beta blocker candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to losing the benefit of beta blockers, such patients are at risk for a withdrawal syndrome if therapy is stopped suddenly. Withdrawal symptoms are most likely to occur with shorter acting drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=see_link\">",
"     \"Withdrawal syndromes with antihypertensive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multitude of \"common\" side effects have been associated with beta blocker therapy. These include depression, fatigue, cognitive impairment, and sexual dysfunction. However, these associations are primarily based upon case series and randomized trials with methodologic flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available data on this issue come from a systematic review of randomized trials of beta blocker therapy, which found no increased risk of depression with beta blocker therapy, and only small increases in fatigue and sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link&amp;anchor=H11#H11\">",
"     \"Major side effects of beta blockers\", section on 'Depression, fatigue, sexual dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers have an adverse effect on plasma lipids by inhibiting the activity of lipoprotein lipase and elevating serum triglycerides and reduce serum HDL-cholesterol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=see_link\">",
"     \"Antihypertensive drugs and lipids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of these changes was evaluated in a post hoc analysis of the Beta Blocker Heart Attack Trial (BHAT), performed prior to the availability of statins, in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    was associated with a 6 percent reduction in HDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/66\">",
"     66",
"    </a>",
"    ]. When the hazard associated with this change was factored into the coronary risk equation, patients receiving beta blockers still had a marked benefit compared to those randomized to placebo. Furthermore, nearly all patients with acute myocardial infarction are now treated with statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346544189\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of beta blocker therapy after MI is not known. Many patients have been continued on this therapy indefinitely based on a 1999 meta-analysis of over 50,000 patients that showed a 23 percent reduction in death at a mean follow-up of 1.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition to the relatively short duration of follow-up, application of the conclusions of this meta-analysis is limited as reperfusion and medical (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and statin) therapies were underutilized routinely. The findings in this meta-analysis were supported by a large observational study published in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more contemporary evaluation of the potential benefit from long-term beta blocker use was made in a 2012 observational study of over 14,000 patients with MI enrolled in the international REACH registry [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients were enrolled in 2003 and 2004 and followed prospectively for up to four years. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke. Propensity score matching identified 3599 pairs of patients with and without beta blocker use.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and statin use (each) was approximately 75 percent. After a median follow-up of 44 months, there was no significant difference in the primary outcome (16.9 versus 18.6 percent, respectively; hazard ratio 0.90, 95% CI 0.79-1.03). Little difference was seen in the event rates in the beta blocker and no beta-blocker groups after two years.",
"   </p>",
"   <p>",
"    A 2013 observational study evaluated outcomes in 5628 patients with STEMI treated with primary percutaneous coronary intervention. During a median follow-up of 1430 days, mortality rates did not differ between patients with and without beta blocker therapy (5.2 versus 6.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/68\">",
"     68",
"    </a>",
"    ]. The absence of a significant difference persisted after multivariate and propensity score matching. However, subgroup analyses revealed that beta blocker treatment was associated with a significantly lower mortality for only high-risk patients, such as those with heart failure. The issue of whether some low risk patients could be discharged without beta blocker should be addressed by a randomized trial.",
"   </p>",
"   <p>",
"    We believe the evidence supports the use of BB blockers in patients with MI for as long as three years. The evidence supporting a longer duration, or indefinite therapy, is limited and thus we make a weak recommendation to do so in patients with high risk features at presentation such as cardiogenic shock, heart failure, or chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'LV dysfunction/heart failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We believe it is reasonable to discontinue beta blocker therapy, using a tapering protocol carried out over a few weeks, in patients with unacceptable side effects, for whom the financial burden is unacceptable, or in those for whom the use of multiple medications is problematic (polypharmacy). There are no known life-threatening side effects (such as proarrhythmia or malignancy) of long-term beta blocker therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of long-term beta blocker therapy in patients with significant left ventricular systolic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link&amp;anchor=H24#H24\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\", section on 'Degree and duration of beta blockade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346544455\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to the use of beta blockers in patients with acute MI is similar to that made in the 2011 guideline on secondary prevention published by the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/69\">",
"     69",
"    </a>",
"    ]. The 2011 European Society of Cardiology guideline for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation does not make a recommendation for indefinite beta blocker use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/53/11098/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a broad range of patients with both ST elevation and non-ST elevation MI, including those with and without revascularization, beta blockers reduce short-term complications and improve long-term survival. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of contraindications, we recommend initiation of oral beta blockers within the first 24 hours in all patients with acute MI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of contraindications, we suggest intravenous, as opposed to oral, beta blockers for hypertensive patients at the time of presentation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients who do not receive a beta blocker during the first 24 hours because of early contraindications should be reevaluated for beta blocker candidacy for subsequent therapy.",
"     </li>",
"     <li>",
"      In the absence of contraindications, we recommend continuing oral beta blockers for a minimum of three years in all patients who have sustained an acute MI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest continuing oral beta blockers indefinitely in higher risk patients, such as those who present with cardiogenic shock, heart failure, or chronic kidney disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H346544189\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The role of long-term beta blocker therapy in patients with significant left ventricular systolic dysfunction is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H12#H12\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Duration of therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link&amp;anchor=H24#H24\">",
"       \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\", section on 'Degree and duration of beta blockade'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/1\">",
"      L&oacute;pez-Send&oacute;n J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/2\">",
"      Ryd&eacute;n L, Ariniego R, Arnman K, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983; 308:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/3\">",
"      Nuttall SL, Toescu V, Kendall MJ. beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 2000; 320:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/4\">",
"      Friedman LM, Byington RP, Capone RJ, et al. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/5\">",
"      Hu K, Gaudron P, Ertl G. Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction: importance of timing of treatment and infarct size. J Am Coll Cardiol 1998; 31:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/6\">",
"      Galcer&aacute;-Tom&aacute;s J, Castillo-Soria FJ, Villegas-Garc&iacute;a MM, et al. Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction. Circulation 2001; 103:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/7\">",
"      Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004; 109:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/8\">",
"      Poulsen SH, Jensen SE, Egstrup K. Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. Am Heart J 1999; 138:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/9\">",
"      Sipahi I, Tuzcu EM, Wolski KE, et al. Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 2007; 147:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/10\">",
"      Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/11\">",
"      Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/12\">",
"      Hjalmarson A, Herlitz J, Holmberg S, et al. The G&ouml;teborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983; 67:I26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/13\">",
"      Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/14\">",
"      Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985; 6:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/15\">",
"      Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/16\">",
"      Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/17\">",
"      Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/18\">",
"      Silvet H, Spencer F, Yarzebski J, et al. Communitywide trends in the use and outcomes associated with beta-blockers in patients with acute myocardial infarction: the Worcester Heart Attack Study. Arch Intern Med 2003; 163:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/19\">",
"      Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/20\">",
"      Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005; 294:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/21\">",
"      Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/22\">",
"      Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989; 320:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/23\">",
"      Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/24\">",
"      Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/27\">",
"      Faxon DP. Beta-blocker therapy and primary angioplasty: what is the controversy? J Am Coll Cardiol 2004; 43:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/28\">",
"      Halkin A, Grines CL, Cox DA, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004; 43:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/29\">",
"      Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004; 43:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/30\">",
"      Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994; 74:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/31\">",
"      Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/32\">",
"      Spargias KS, Hall AS, Greenwood DC, Ball SG. beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 1999; 81:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/33\">",
"      Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/34\">",
"      Lichstein E, Hager WD, Gregory JJ, et al. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group. J Am Coll Cardiol 1990; 16:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/35\">",
"      Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/36\">",
"      Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/37\">",
"      Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/38\">",
"      Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983; 6:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/39\">",
"      Malmberg K, Herlitz J, Hjalmarson A, Ryd&eacute;n L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J 1989; 10:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/40\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/41\">",
"      Au DH. Use of beta blockers in patients with COPD. Thorax 2008; 63:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/42\">",
"      Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342:d2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/43\">",
"      Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/44\">",
"      Califf RM, Lokhnygina Y, Velazquez EJ, et al. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol 2009; 104:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/45\">",
"      Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/46\">",
"      Solomon SA, Ramsay LE, Yeo WW, et al. beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991; 303:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/47\">",
"      Thadani U, Whitsett TL. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med 1991; 151:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/48\">",
"      Barron HV, Rundle AC, Gore JM, et al. Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2. Am J Cardiol 2000; 85:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/49\">",
"      Shivkumar K, Schultz L, Goldstein S, Gheorghiade M. Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. Am Heart J 1998; 135:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/50\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/51\">",
"      Mrdovic IB, Savic LZ, Perunicic JP, et al. Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 2007; 154:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/52\">",
"      Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57:43F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/53\">",
"      Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/54\">",
"      Kloner RA, Hale S. Unraveling the complex effects of cocaine on the heart. Circulation 1993; 87:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/55\">",
"      Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/56\">",
"      Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995; 25:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/57\">",
"      Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995; 26:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/58\">",
"      Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/59\">",
"      Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/60\">",
"      Kennedy HL, Rosenson RS. Physician use of beta-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol 1995; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/61\">",
"      Gislason GH, Rasmussen JN, Abildstr&oslash;m SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/62\">",
"      Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/63\">",
"      Miller CD, Roe MT, Mulgund J, et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. Am J Med 2007; 120:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/64\">",
"      Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002; 40:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/65\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/66\">",
"      Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience. Am J Cardiol 1990; 65:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/67\">",
"      Bangalore S, Steg G, Deedwania P, et al. &beta;-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/68\">",
"      Nakatani D, Sakata Y, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol 2013; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/69\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/53/11098/abstract/70\">",
"      Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 96 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11098=[""].join("\n");
var outline_f10_53_11098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overall benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patients who undergo reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patients treated with antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patients with potential contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - COPD/asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - LV dysfunction/heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MODES OF ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Early administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Late administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Early versus late administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Heart rate goal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346544189\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H346544455\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/96\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/96|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/13/23774\" title=\"figure 1\">",
"      Propranolol after acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/50/17198\" title=\"figure 2\">",
"      Beta blocker Q wave NQWMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/22/30062\" title=\"figure 3\">",
"      CAST beta blocker AA drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/16/18701\" title=\"figure 4\">",
"      EMIAT beta blocker amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17918\" title=\"figure 5A\">",
"      Outcome beta blocker amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/49/41757\" title=\"figure 5B\">",
"      Mortality beta blocker amio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/61/31709\" title=\"figure 6\">",
"      Beta blocker MI COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/42/31405\" title=\"figure 7\">",
"      Beta blocker in HF after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/27/22973\" title=\"figure 8\">",
"      Beta blocker persist ST depress",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=related_link\">",
"      Antihypertensive drugs and lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=related_link\">",
"      Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41289?source=related_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_53_11099="Classification of DCIS";
var content_f10_53_11099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed classification systems for ductal carcinoma in situ",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Lagios*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Van Nuys&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        European&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low grade",
"       </td>",
"       <td>",
"        Non-high grade without necrosis",
"       </td>",
"       <td>",
"        Well differentiated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermediate grade",
"       </td>",
"       <td>",
"        Non-high grade with necrosis",
"       </td>",
"       <td>",
"        Intermediately differentiated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High grade",
"       </td>",
"       <td>",
"        High grade",
"       </td>",
"       <td>",
"        Poorly differentiated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     * Adapted from Lagios MD, Margolin FR, Westdahl PR, Rose MR. Cancer 1989; 63:618.",
"     <br>",
"      &bull; Silverstein MJ, Poller DN, Waisman JR, et al. Lancet 1995; 345:1154.",
"      <br>",
"       &Delta; Holland R, Peterse JL, Millis RR, et al. Semin Diagn Pathol 1994; 11:167.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11099=[""].join("\n");
var outline_f10_53_11099=null;
var title_f10_53_11100="Inhaled medications that require specific nebulizers";
var content_f10_53_11100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inhaled medications that require specific nebulizers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specialized nebulizer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam",
"       </td>",
"       <td>",
"        Mesh: Altera",
"        <sup>",
"         &reg;",
"        </sup>",
"        Nebulizer System",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Budesonide",
"       </td>",
"       <td>",
"        Jet or mesh nebulizers, but NOT ultrasonic",
"       </td>",
"       <td>",
"        Ultrasonic nebulizers cannot be used for budesonide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dornase alpha (DNase)",
"       </td>",
"       <td>",
"        Jet: Pulmo-Aide",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Pari-Proneb",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Mobilaire",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Porta-Neb",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Pari-Baby&trade;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iloprost",
"       </td>",
"       <td>",
"        Jet: Prodose AAD (respironics)",
"        <br/>",
"        Mesh: I-neb AAD (respironics)",
"       </td>",
"       <td>",
"        Specialized nebulizer needed for accurate dosing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentamidine",
"       </td>",
"       <td>",
"        Jet: Respirgard II",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Small volume, one-way valve to prevent contamination of ambient environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ribavirin",
"       </td>",
"       <td>",
"        Jet: Viratek Small-Particle Aerosol Generator (SPAG-2",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        Small particle size; scavenging system to minimize contamination of the ambient environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin",
"       </td>",
"       <td>",
"        Jet: PARI-LC PLUS&trade;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treprostinil",
"       </td>",
"       <td>",
"        Ultrasonic: Optineb",
"       </td>",
"       <td>",
"        Specialized nebulizer needed for accurate dosing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11100=[""].join("\n");
var outline_f10_53_11100=null;
var title_f10_53_11101="Treatment of HTN by underlying disease";
var content_f10_53_11101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Considerations for individualizing antihypertensive therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antihypertensive drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Compelling indications (major improvement in outcome independent of blood pressure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systolic heart failure",
"       </td>",
"       <td>",
"        ACE inhibitor or ARB, beta blocker, diuretic, aldosterone antagonist*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-myocardial infarction",
"       </td>",
"       <td>",
"        ACE inhibitor, beta blocker, aldosterone antagonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteinuric chronic kidney disease",
"       </td>",
"       <td>",
"        ACE inhibitor and/or ARB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angina pectoris",
"       </td>",
"       <td>",
"        Beta blocker, calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial fibrillation rate control",
"       </td>",
"       <td>",
"        Beta blocker, nondihydropyridine calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial flutter rate control",
"       </td>",
"       <td>",
"        Beta blocker, nondihydropyridine calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Likely to have a favorable effect on symptoms in comorbid conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign prostatic hypertrophy",
"       </td>",
"       <td>",
"        Alpha blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Essential tremor",
"       </td>",
"       <td>",
"        Beta blocker (noncardioselective)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperthyroidism",
"       </td>",
"       <td>",
"        Beta blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Migraine",
"       </td>",
"       <td>",
"        Beta blocker, calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteoporosis",
"       </td>",
"       <td>",
"        Thiazide diuretic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perioperative hypertension",
"       </td>",
"       <td>",
"        Beta blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raynaud's syndrome",
"       </td>",
"       <td>",
"        Dihydropyridine calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angioedema",
"       </td>",
"       <td>",
"        ACE inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchospastic disease",
"       </td>",
"       <td>",
"        Beta blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression",
"       </td>",
"       <td>",
"        Reserpine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver disease",
"       </td>",
"       <td>",
"        Methyldopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pregnancy",
"       </td>",
"       <td>",
"        ACE inhibitor, ARB (includes women likely to become pregnant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Second or third degree heart block",
"       </td>",
"       <td>",
"        Beta blocker, nondihydropyridine calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        May have adverse effect on comorbid conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression",
"       </td>",
"       <td>",
"        Beta blocker, central alpha agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gout",
"       </td>",
"       <td>",
"        Diuretic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperkalemia",
"       </td>",
"       <td>",
"        Aldosterone antagonist, ACE inhibitor, ARB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyponatremia",
"       </td>",
"       <td>",
"        Thiazide diuretic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renovascular disease",
"       </td>",
"       <td>",
"        ACE inhibitor or ARB",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A survival benefit from an aldosterone antagonist has only been demonstrated in patients with advanced heart failure; in patients with less severe disease, an aldosterone antagonist is primarily given for hypokalemia",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003; 289:2560.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11101=[""].join("\n");
var outline_f10_53_11101=null;
var title_f10_53_11102="Time of abortus expulsion";
var content_f10_53_11102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Time of expulsion of conceptus in 1720 women with successful medical termination of pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The women received oral mifepristone 600 mg&nbsp;at visit 1 and oral misoprostol 400 mcg two days later (visit 2). \"Uncertain\" indicates that expulsion occurred within the first 24 hours after misoprostol was given, but the exact time was not known.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Spitz, IM, Bardin, CW, Benton, L, Robbins, A. N Engl J Med 1998; 388:1241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11102=[""].join("\n");
var outline_f10_53_11102=null;
var title_f10_53_11103="Lens trauma";
var content_f10_53_11103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lens trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A photograph of a patient following blunt trauma. The lens is laterally dislocated (subluxed) as evidenced by the visible lens edge in this photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Kathryn A. Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_53_11103=[""].join("\n");
var outline_f10_53_11103=null;
